Related Experiment Video
Updated: Jan 27, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Activation of p53-dependent responses in tumor cells treated with a PARC-interacting peptide
Roberta Vitali1, Vincenzo Cesi, Barbara Tanno
1ENEA Research Center Casaccia, Section of Toxicology and Biomedical Sciences, Via Anguillarese, 301, Rome 00123, Italy.
Abstract:
We tested the activity of a p53 carboxy-terminal peptide containing the PARC-interacting region in cancer cells with wild type cytoplasmic p53. Peptide delivery was achieved by fusing it to the TAT transduction domain (TAT-p53-C-ter peptide). In a two-hybrid assay, the tetramerization domain (TD) of p53 was necessary and sufficient to bind PARC. The TAT-p53-C-ter peptide disrupted the PARC-p53 complex. Peptide treatment caused p53 nuclear relocation, p53-dependent changes in gene expression and enhancement of etoposide-induced apoptosis. These studies suggest that PARC-interacting peptides are promising candidates for the enhancement of p53-dependent apoptosis in tumors with wt cytoplasmic p53.
Insights
A novel peptide targeting the PARC-interacting region of p53 enhances cancer cell apoptosis. This peptide, delivered via the TAT transduction domain, disrupts the PARC-p53 complex, promoting tumor cell death.
Area of Science:
- Molecular Biology
- Cancer Research
- Cellular Biology
Background:
- Wild-type cytoplasmic p53 plays a crucial role in cancer cell apoptosis.
- PARC (p53-associated protein) interacts with p53, influencing its cellular localization and function.
- Targeting protein-protein interactions offers a potential therapeutic strategy in oncology.
Purpose of the Study:
- To investigate the therapeutic potential of a p53 carboxy-terminal peptide fused to the TAT transduction domain (TAT-p53-C-ter) for cancer treatment.
- To determine if the tetramerization domain (TD) of p53 is essential for PARC binding.
- To evaluate the peptide's ability to disrupt the PARC-p53 complex and induce apoptosis in cancer cells.
Main Methods:
- Utilized a two-hybrid assay to assess the interaction between p53's tetramerization domain and PARC.
- Developed and employed a TAT-p53-C-ter peptide for targeted delivery into cancer cells.
- Analyzed p53 nuclear relocation, gene expression changes, and etoposide-induced apoptosis following peptide treatment.
Main Results:
- The tetramerization domain (TD) of p53 was found to be necessary and sufficient for binding to PARC.
- The TAT-p53-C-ter peptide effectively disrupted the endogenous PARC-p53 complex within cancer cells.
- Peptide treatment led to the nuclear translocation of p53, altered p53-dependent gene expression, and enhanced apoptosis induced by etoposide.
Conclusions:
- PARC-interacting peptides, specifically the TAT-p53-C-ter peptide, demonstrate significant potential for enhancing p53-dependent apoptosis.
- These peptides represent a promising therapeutic strategy for tumors harboring wild-type cytoplasmic p53.
- Targeting the PARC-p53 interaction could be a viable approach to improve cancer treatment outcomes.
Related Concept Videos
Cell-mediated Immune Responses
Peptide Bonds
Frequency-dependent Selection
Temperature Dependence on Reaction Rate
Atoms, molecules, or ions must collide before they can react with each other. Atoms must be close together to form chemical bonds. This premise is the basis for a theory that explains many observations regarding chemical kinetics, including factors affecting reaction rates.
The collision theory is based on the postulates that (i) the reaction rate is proportional to the rate of reactant collisions, (ii) the reacting species collide in an orientation allowing contact between...
Contact-dependent Signaling
Gap Junctions
In animal cells, gap junctions are formed...
Drug Dependence

